Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259815 | 0.96 | MTNR1A (0.50) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL3812256 | 0.92 | MTNR1A (0.51) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL5434257 | 0.84 | KDM4E (0.54) | MTNR1AMTNR1BKDM4EUSP2ALDH1A1 | |
| SCHEMBL8078291 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4EMEN1KMT2A | |
| SCHEMBL12450012 | 0.83 | MTNR1A (0.57) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL2020434 | 0.81 | MTNR1A (0.59) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL1395799 | 0.80 | HTR2A (0.52) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL2023775 | 0.79 | HTR2A (0.51) | MTNR1AMTNR1BHTR2AHTR2CKMT2A | |
| SCHEMBL1719811 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL8081516 | 0.78 | TP53 (0.47) | MTNR1AMTNR1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160137644-A1 | METHOD FOR PRODUCING TRICYCLIC HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160137644-A1 | METHOD FOR PRODUCING TRICYCLIC HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-19 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1483265-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003076442-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076442-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-5198437-A | 5-hydroxytryptamine antagonist | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1993-03-30 | — | — | US | disclosed |
| EP-0322016-A1 | 1,7-Annelated indolecarboxylic acid esters and -amides | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | MTNR1A 1002/4885MTNR1B 1120/4885HTR2A 4207/4885 |
| US-20160137644-A1 | METHOD FOR PRODUCING TRICYCLIC HETEROCYCLIC COMPOUND | CYP3A4, CYP3A5, CYP3A43 | MTNR1A 4369/4885MTNR1B 4493/4885HTR2A 2490/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | MTNR1A 1569/4885MTNR1B 1201/4885HTR2A 4255/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | MTNR1A 904/4885MTNR1B 1009/4885HTR2A 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.